Screening of antipsychotic drugs in animal models

Drug Development Research

Volumn 50, Issue 3-4, 2000, Pages 235-249

  Weiner, Ina ^a   Gaisler, Inna ^a   Schiller, Daniela ^a   Green, Amit ^a   Zuckerman, Lee ^a   Joel, Daphna ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Animal model; Antipsychotic drugs; Forced swim test; Latent inhibition; Schizophrenia

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; RITANSERIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; BEHAVIOR DISORDER; BRAIN INJURY; COGNITION; DRUG ACTIVITY; DRUG POTENTIATION; DRUG SCREENING; FORCED SWIMMING TEST; NONHUMAN; PSYCHOSIS; RAT; REVIEW; SCHIZOPHRENIA; THEORY;

EID: 0033809127     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/1098-2299(200007/08)50:3/4<235::AID-DDR7>3.0.CO;2-R     Document Type: Review

References (161)

1. HPA axis and cytokines dysregulation in schizophrenia: Potential implications for the antipsychotic treatment
2. The disorder of consciousness in schizophrenia
3. Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of d-amphetamine
4. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence
5. The effects of electrolytic median raphe lesions on two measures of latent inhibition
6. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine
7. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response
8. Differential performance of acute and chronic schizophrenics in a latent inhibition task
9. Latent inhibition and 'psychotic proneness' in normal subjects
10. Akinesia: A syndrome common to parkinsonism, retarded depression, and negative symptoms of schizophrenia
11. Effect of repeated treatment with desipramine in the behavioral 'despair' test in rats: Antagonism by 'atypical' but not 'classical' neuroleptics or anti-adrenergic drugs
12. Are high schizotypal normal participants distractible or limited in attentional resources? A study of latent inhibition as a function of masking task load and schizotypy
13. The glycine/NMDA receptor antagonist, 1-701, 324 reverses isolation-induced deficits in prepulse inhibition in the rat
14. Effects of antidepressants and anticholinergics in a mouse 'behavioral despair' test
15. New insights into the biology of schizophrenia through the mechanism of action of clozapine
16. Deficit and nondeficit forms of schizophrenia: The concept
17. The effects of ritanserin, RU 24969 and 8-OH-DPAT on latent inhibition in the rat
18. 5,7-Dihydroxytryptamine lesions in the fornix-fimbria attenuate latent inhibition
19. Latent inhibition: The effects of haloperidol and hippocampal lesions
20. Haloperidol enhancement of latent inhibition: Relation to therapeutic action?
21. Depression in schizophrenia: A comparison of three measures
22. Effects of atypical antipsychotic agents on social behavior in rodents
23. Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors
24. Attentional markers of schizophrenia: Evidence from the New York high-risk study
25. Entorhinal but not hippocampal or subicular lesions disrupt latent inhibition in rats
26. Restoration of latent inhibition by olanzapine but not haloperidol in entorhinal cortexlesioned rats
27. Limbic/mesolimbic connections and the pathogenesis of schizophrenia
28. Memory for attended and nominally unattended stimuli in low and high psychotic-prone normal subjects: The effects of test-anticipation
29. Amphetamine-produced attenuation of latent inhibition is modulated by stimulus preexposure duration: Implications for schizophrenia
30. Latent inhibition and recall/recognition of irrelevant stimuli as a function of preexposure duration in high and low psychotic-prone normals
31. Effects of smoking status and schizotypy on latent inhibition
32. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants
33. Effects of antipsychotics on cognitive behaviour in rats using the delayed non-match to position paradigm
34. Effects of antipsychotic drugs on latent inhibition: Sensitivity and specificity of an animal behavioral model of clinical drug action
35. Activity of 'seroquel' (ICI204,636) in animal models for atypical properties of antipsychotics: A comparison with clozapine
36. The effects of pre and postweaning rearing conditions on latent inhibition and partial reinforcement extinction effect in male rats
37. Latent inhibition is unaffected by direct dopamine agonists
38. Long-term attentional deficit in nonhandled males: Possible involvement of the dopaminergic system
39. The latent inhibition model of schizophrenic attention disorder. Haloperidol and sulpiride enhance rats' ability to ignore irrelevant stimuli
40. From an animal model of an attentional deficit towards new insights into the pathophysiology of schizophrenia
41. Attentional capacity dysfunction and arousal in schizophrenia
42. Intermittent neuroleptic treatment induces long-lasting abnormal mouthing in the rat
43. Effects of neuroleptics displaying antidepressant activity on behavior of rats in the forced swimming test
44. Antagonism of amphetamine-induced disruption of latent inhibition by the atypical antipsychotic olanzapine in rats
45. PD-135,158, a cholecystokinin(B) antagonist, enhances latent inhibition
46. The neuropsychology of schizophrenia
47. Abolition of latent inhibition in acute, but not chronic, schizophrenics
48. Abolition of latent inhibition by a single 5 mg dose of d-amphetamine in man
49. Latent inhibition in drug naive schizophrenics: Relationship to duration of illness and dopamine D2 binding using SPET
50. The role of mesolimbic dopaminergic and retrohippocampal afferents to the nucleus accumbens in latent inhibition: Implications for schizophrenia
51. Latent inhibition: The nucleus accumbens connection revisited
52. Disruption of latent inhibition in rats with postnatal hippocampal lesions
53. Serotonin and antipsychotic drug effects in latent inhibition
54. The effects of haloperidol and clozapine on the disruption of sensorimotor gating induced by the noncompetitive glutamate antagonist MK-801
55. Muscimol inactivation of the dorsal hippocampus impairs contextual retrieval of fear memory
56. Selective hippocampal lesions abolish the contextual specificity of latent inhibition and conditioning
57. Behavioral consequences of long-term treatment with neuroleptic drugs
58. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties
59. The atypical antipsychotic, remoxipride, blocks phencyclidine-induced disruption of prepulse inhibition in the rat
60. Modulation of latent inhibition in the rat by altered dopamine transmission in the nucleus accumbens at the time of conditioning
61. Current problems with the pharmacotherapy of schizophrenia
62. Effect of chronic administration of antidepressants on duration of immobility in rats forced to swim
63. The positive-negative distinction in drug-free schizophrenic patients
64. Differential effects of intra-accumbens and systemic amphetamine on latent inhibition using an on-baseline, within-subject conditioned suppression paradigm
65. Amphetamine-induced disruptions of latent inhibition are reinforcer mediated: Implications for animal models of schizophrenic attentional dysfunction
66. Effects of the neuroleptic alpha-flupenthixol on latent inhibition in aversively- and appetitively-motivated paradigms: Evidence for dopamine-reinforcer interactions
67. Drug treatment of the negative symptoms of schizophrenia
68. Mechanisms of action of atypical antipsychotic drugs: A critical analysis
69. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects - Role of 5HT(2) receptors
70. Depression, affect and negative symptoms in schizophrenia
71. Forebrain monoamines and associative learning: I. Latent inhibition and conditioned inhibition
72. Latent inhibition
73. Latent inhibition in humans: Data, theory, and implications for schizophrenia
74. Conditioned attention theory
75. Negative symptoms and affective disturbance in schizophrenia and related disorders
76. Disorders of attention and perception in early schizophrenia
77. Adult schizophrenia following prenatal exposure to an influenza epidemic
78. Clinical studies on the mechanism of action of clozapine: The dopamine-serotonin hypothesis of schizophrenia
79. The dopamine hypothesis of schizophrenia: A review
80. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3- phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agents
81. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3- phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile
82. The behavioral pharmacology of olanzapine, a novel 'atypical' antipsychotic agent
83. Effects of clozapine on latent inhibition in the rat
84. Reversal of amphetamine-induced behaviours by MDL 100,907, a selective 5-HT2A antagonist
85. Effects of anti-depressants on phencyclidine-induced enhancement of immobility in a forced swimming test in mice
86. Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: A new model of schizophrenia
87. Information processing and attentional functioning in the developmental course of the schizophrenic disorder
88. Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain
89. The dopamine D2 antagonist remoxipride acts in vivo on a subpopulation of dopamine D2 receptors
90. Serotonergic mediation of the effects of fluoxetine, but not desipramine, in the rat forced swimming test
91. Haloperidol potentiation of latent inhibition in rats: Evidence for a critical role at conditioning rather than pre-exposure
92. Depression: A new animal model sensitive to antidepressant treatments
93. Acute and long-term effectiveness of clozapine in treatment-resistant psychotic depression
94. Biochemical findings of negative symptoms in schizophrenia and their putative relevance to pharmacologic treatment - A review
95. Amphetamine-induced disruption and haloperidol-induced potentiation of latent inhibition depend on the nature of the stimulus
96. Haloperidol-induced potentiation of latent inhibition: Interaction with parameters of conditioning
97. Phencyclidine-induced stereotyped behaviour and social isolation in rats: A possible animal model of schizophrenia
98. Effect of novel antipsychotic drugs on phencyclidine-induced stereotyped behaviour and social isolation in the rat social interaction test
99. Effects of typical and atypical antipsychotic drugs on response decrement patterns in rats
100. Relationship among negative, positive, and depressive symptoms in schizophrenia and psychotic depression
101. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding
102. Ziprasidone (CP-88,059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity
103. Clozapine-induced potentiation of latent inhibition is due to its action in the conditioning stage: Implications for the mechanism of action of antipsychotic drugs
104. The latent inhibition model dissociates between clozapine, haloperidol and ritanserin
105. Gender- and age-dependent differences in latent inhibition following pre-weaning non-handling: Implications for a neurodevelopmental animal model of schizophrenia
106. Differential effect of antipsychotics on place navigation of rats in the Morris water maze - A comparative study between novel and reference antipsychotics
107. The dopamine hypothesis of schizophrenia: Focus on the dopamine receptor
108. Differential effects of microinjections of d-amphetamine into the nucleus accumbens or the caudate putamen on the rat's ability to ignore an irrelevant stimulus
109. Disruption of latent inhibition following systemic administration of parachlorophenylalanine (PCPA)
110. Differential effects of lesions in medial and dorsal raphe of the rat: Latent inhibition and septo-hippocampal serotonin levels
111. Disrupted latent inhibition in the rat with chronic amphetamine or haloperidol-induced supersensitivity: Relationship to schizophrenic attention disorder
112. Latent inhibition in conditioned emotional response: C-fos immunolabelling evidence for brain areas involved in the rat
113. Clozapine and haloperidol in an animal model of sensorimotor gating deficits in schizophrenia
114. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients
115. Latent inhibition in schizophrenia
116. Both electrolytic and excitotoxic lesions of nucleus accumbens disrupt latent inhibition of learning in rats
117. Expert commentary: Neurobiological substrate of dimensions of schizophrenic illness
118. Mutability and relationship between positive and negative symptoms during neuroleptic treatment in schizophrenia
119. Effects of nicotine and amphetamine on latent inhibition in human subjects
120. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia
121. A viral-anatomical explanation of schizophrenia
122. Enhancement of latent inhibition in the rat by the atypical antipsychotic agent remoxipride
123. Enhancement of latent inhibition in the rat at a high dose of clozapine
124. Latent inhibition and autonomic responses: A psycholophysiological approach
125. Examination of drug-induced and isolation-induced disruptions of prepulse inhibition as models to screen antipsychotic drugs
126. Cerebral mechanisms, autonomic responsiveness, and attention in schizophrenia
127. Antagonism of amphetamine-induced disruption of latent inhibition in rats by haloperidol and ondansetron: Implications for a possible antipsychotic action of ondansetron
128. Implications of normal brain development for the pathogenesis of schizophrenia
129. Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: A search for common ground
130. Neural substrates of latent inhibition: The switching model
131. Facilitation of latent inhibition by haloperidol in rats
132. The switching model of latent inhibition: An update of neural substrates
133. Chronic amphetamine and latent inhibition
134. Abolition of the expression but not the acquisition of latent inhibition by chronic amphetamine in rats
135. The effects of early handling on latent inhibition in male and female rats
136. Facilitation of the expression but not the acquisition of latent inhibition by haloperidol in rats
137. Early handling and latent inhibition in the conditioned suppression paradigm
138. Latent inhibition is not affected by acute or chronic administration of 6 mg/kg dl-amphetamine
139. Disruption of latent inhibition by acute administration of low doses of amphetamine
140. A neuroleptic-like effect of ceronapril on latent inhibition
141. The effects of the new antipsychotic, sertindole, on latent inhibition in rats
142. Differential involvement of the shell and core subterritories of the nucleus accumbens in latent inhibition and amphetamine-induced activity
143. The latent inhibition model of schizophrenia: Further validation using the atypical neuroleptic, clozapine
144. Amphetamine-induced disruption of latent inhibition depends on the nature of the stimulus
145. Haloperidol- and clozapine-induced enhancement of latent inhibition with extended conditioning: Implications for the mechanism of action of neuroleptic drugs
146. Amphetamine-induced disruption of latent inhibition is not reinforcer-mediated
147. Disrupted and undisruptable latent inhibition following shell and core lesions
148. The latent inhibition model of schizophrenia
149. Effects of 4 antipsychotics on punished responding in rats
150. Anti-psychotic drug effects in a model of schizophrenic attentional disorder: A randomised trial of the effects of haloperidol on latent inhibition in healthy people
151. Haloperidol enhances latent inhibition in visual tasks in healthy people
152. Reduced latent inhibition in people with schizophrenia: An effect of psychosis or of its treatment
153. Behavioural models in psychopharmacology
154. Behavioral effects of neuroleptics
155. Latent inhibition in rats is abolished by NMDA-induced neuronal loss in the retrohippocampal region but this lesion effect can be prevented by systemic haloperidol treatment
156. Latent inhibition of conditioned dopamine release in rat nucleus accumbens